Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07105254 · ClinicalTrials.gov registry record · Phase 2
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
A Phase 2 study of Non-segmental Vitiligo, sponsored by Derm Texas, P.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07105254 is a Phase 2 study of Non-segmental Vitiligo that is actively recruiting participants, run by Derm Texas, P. The registered enrollment target is 20 participants, below the 222-participant average among 5 other Non-segmental Vitiligo trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07105254, a Phase 2 study of Non-segmental Vitiligo, is actively recruiting participants, sponsored by Derm Texas, P.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)
Conditions Studied
Interventions
- DRUG Roflumilast topical 0.3% foam
Study Locations (1)
Texas
- Derm Texas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-08-01 |
| Est. Completion | 2026-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07105254
The ClinicalTrials.gov registry entry for NCT07105254 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 5 other Non-segmental Vitiligo trials with a reported enrollment target (91% lower). The listed sponsor is Derm Texas, P, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-segmental Vitiligo appearing as the primary indexed condition, and to 1 intervention - of which Roflumilast topical 0.3% foam is the first listed.
NCT07105254 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07105254 about?
NCT07105254 is a clinical study titled "An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)". An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)
What is the current status of trial NCT07105254?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-08-01. Estimated completion is 2026-06-15.
What conditions does trial NCT07105254 study?
This clinical trial studies the following conditions: Non-segmental Vitiligo.
What interventions are being tested in trial NCT07105254?
The interventions under investigation include: Roflumilast topical 0.3% foam (DRUG).
Who is sponsoring clinical trial NCT07105254?
This trial is sponsored by Derm Texas, P, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07105254 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-segmental Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
RECRUITING · Phase 2
-
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
COMPLETED · Phase 2
-
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.